Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
暂无分享,去创建一个
O. Cars | G. Drusano | H. Derendorf | M. Dudley | J. Mouton
[1] K. Drlica. The mutant selection window and antimicrobial resistance. , 2003, The Journal of antimicrobial chemotherapy.
[2] O. Cars,et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. , 2002, International journal of antimicrobial agents.
[3] J. Andrews,et al. Determination of minimum inhibitory concentrations. , 2001, The Journal of antimicrobial chemotherapy.
[4] G. Drusano,et al. Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint , 2001, Antimicrobial Agents and Chemotherapy.
[5] Jerome J. Schentag,et al. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. , 1997, The Journal of antimicrobial chemotherapy.
[6] L. Danziger,et al. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens , 1997, Antimicrobial agents and chemotherapy.
[7] P. Maire,et al. Dosage Regimens of Antibacterials , 1996 .
[8] W. Greco,et al. The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.
[9] Jerome J. Schentag,et al. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar , 1994, Antimicrobial Agents and Chemotherapy.
[10] J J Schentag,et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.
[11] J. Spivey. The postantibiotic effect. , 1992, Clinical pharmacy.
[12] Jerome J. Schentag,et al. Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin , 1991, DICP : the annals of pharmacotherapy.
[13] O. Cars,et al. Pharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro , 1991, Antimicrobial Agents and Chemotherapy.
[14] B. Guglielmo,et al. Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens , 1988, Antimicrobial Agents and Chemotherapy.
[15] S. Barriere,et al. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. , 1985, The Journal of antimicrobial chemotherapy.
[16] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[17] V. Lorian. Antibiotics in laboratory medicine , 2005 .
[18] Johan W Mouton,et al. Pharmacokinetic/Pharmacodynamic Modelling of Antibacterials In Vitro and In Vivo Using Bacterial Growth and Kill Kinetics , 2005, Clinical pharmacokinetics.
[19] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .